FDG PET Detection of Neurolymphomatosis in Diffuse Large B-cell Lymphoma, With Neuropathy as Presenting Complaint
Clinical Nuclear Medicine Open · 2025
DOI: 10.1097/nm9.0000000000000018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nuclear Medicine Open, 2025. Verfasst von Kersandra Begley und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Two patients with neurolymphomatosis as the initial manifestation of diffuse large B-cell lymphoma are presented. Both patients experienced mixed severe sensorimotor neuropathy as their presenting complaint. Subsequently, both had a prolonged interval to diagnosis, 6 and 14 months, respectively. MRI or CT imaging in both cases was nondiagnostic, and FDG PET/CT was used to demonstrate intense uptake throughout spinal nerves, leading to biopsy and definitive diagnosis. FDG PET/CT is a valuable investigation that should be considered early in cases of intractable progressive neuropathy to eliminate malignant differential causes.
Zitieren
APA
Begley, K., & Quinn, R. (2025). FDG PET Detection of Neurolymphomatosis in Diffuse Large B-cell Lymphoma, With Neuropathy as Presenting Complaint. Clinical Nuclear Medicine Open. https://doi.org/10.1097/nm9.0000000000000018
Vancouver
Begley K, Quinn R. FDG PET Detection of Neurolymphomatosis in Diffuse Large B-cell Lymphoma, With Neuropathy as Presenting Complaint. Clinical Nuclear Medicine Open. 2025. doi:10.1097/nm9.0000000000000018
BibTeX
@article{Begley2025,
author = {Begley, Kersandra and Quinn, Richard},
title = {FDG PET Detection of Neurolymphomatosis in Diffuse Large B-cell Lymphoma, With Neuropathy as Presenting Complaint},
journal = {Clinical Nuclear Medicine Open},
year = {2025},
doi = {10.1097/nm9.0000000000000018}
}
EUVIMED